Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GlaxoSmithKline is spending $100 million to increase production at its vaccine facility in Hamilton, Montana. The site makes adjuvants—immune-stimulating molecules—for vaccines, including Shingrix, designed to prevent shingles in adults aged 50 and older. GSK hasn’t been able to keep up with demand since Shingrix was approved in the US in 2017. The Shingrix adjuvant contains a saponin molecule extracted from the Chilean soap bark tree.
This article has been sent to the following recipient: